Patient Voice Aotearoa’s Dr Malcolm Mulholland appeared before the Health Select Committee to voice opposition to parts of the Therapeutic Products Bill on behalf of patients in New Zealand.
“The Bill threatens to obstruct access to unfunded medicines by making it illegal for New Zealanders to import prescription medicines via post” says Dr Mulholland, adding: “We are aware of countless Kiwis who have turned to importing medicines to save their lives. The Therapeutic Products Bill in its current form would be a death sentence for these patients.”
Patient Voice Aotearoa is also gravely concerned about the Bill creating a barrier to clinical trials, and making it illegal for patients, advocates, doctors, and media from publicly discussing the need to fund unfunded medicines.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze